Review of dual and triple gut peptide agonists on the horizon covers tirzepatide, retatrutide, CagriSema, and other multi-target obesity drugs approaching clinical use.
Key findingReview of dual and triple gut peptide agonists on the horizon covers tirzepatide, retatrutide, Cagri
What the researchers found
Review of dual and triple gut peptide agonists on the horizon covers tirzepatide, retatrutide, CagriSema, and other multi-target obesity drugs approaching clinical use.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
No specific numerical outcomes highlighted in abstract; review synthesizes data across multiple drug candidates and trials.
How the study worked
In publication.
Who was studied
Patients with type 2 diabetes and/or obesity
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data.
Current obesity reports, 14(1), 34
Citation
Anastasiou, Ioanna Α; Argyrakopoulou, Georgia; Dalamaga, Maria; Kokkinos, Alexander. (2025). Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data.. Current obesity reports, 14(1), 34. https://doi.org/10.1007/s13679-025-00623-1